Mallinckrodt Ireland Drug Patent Portfolio
Mallinckrodt Ireland owns 1 orange book drug protected by 1 US patent Given below is the list of Mallinckrodt Ireland's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10335452 | Method of treating patients with hepatorenal syndrome type 1 | 05 Apr, 2037 | Active |
Latest Legal Activities on Mallinckrodt Ireland's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Mallinckrodt Ireland.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 03 Jan, 2023 | US10335452 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 02 Jul, 2019 | US10335452 |
|
Recordation of Patent Grant Mailed
Critical
| 02 Jul, 2019 | US10335452 |
|
Email Notification
Critical
| 13 Jun, 2019 | US10335452 |
|
Issue Notification Mailed
Critical
| 12 Jun, 2019 | US10335452 |
| Dispatch to FDC | 05 Jun, 2019 | US10335452 |
|
Application Is Considered Ready for Issue
Critical
| 22 May, 2019 | US10335452 |
|
Issue Fee Payment Verified
Critical
| 21 May, 2019 | US10335452 |
|
Issue Fee Payment Received
Critical
| 21 May, 2019 | US10335452 |
|
Electronic Review
Critical
| 25 Feb, 2019 | US10335452 |
|
Email Notification
Critical
| 25 Feb, 2019 | US10335452 |
|
Mail Notice of Allowance
Critical
| 25 Feb, 2019 | US10335452 |
|
Notice of Allowance Data Verification Completed
Critical
| 20 Feb, 2019 | US10335452 |
| Miscellaneous Incoming Letter | 08 Feb, 2019 | US10335452 |
|
Electronic Review
Critical
| 21 Dec, 2018 | US10335452 |
Mallinckrodt Ireland's Family Patents
Mallinckrodt Ireland Drug List
Given below is the complete list of Mallinckrodt Ireland's drugs and the patents protecting them.
1. Terlivaz
Terlivaz is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10335452 | Method of treating patients with hepatorenal syndrome type 1 |
05 Apr, 2037
(12 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Terlivaz's drug page